Misbah Tahir is the Chief Financial Officer at Maze Therapeutics Inc., a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. With more than 20 years of experience in biotechnology and pharmaceutical finance, Misbah is a Chartered Accountant who began her career at Deloitte, rising to Senior Manager where she specialized in audit and advisory services for life sciences clients. Her early expertise laid the foundation for a career marked by strategic financial leadership in high-growth environments. Before joining Maze in 2022, Misbah served as CFO at Rallybio Corporation, guiding the company through its 2021 IPO and raising over $400 million in equity financings to fuel pipeline advancement. Previously, as Vice President of Finance at Gossamer Bio, she managed financial operations amid clinical expansion and business development. At Alexion Pharmaceuticals (now AstraZeneca Rare Disease), she directed global financial reporting, treasury, and M&A transactions, contributing to key acquisitions and operational efficiencies. In her role at Maze Therapeutics, Misbah oversees all financial functions, including strategic planning, budgeting, investor relations, and capital raising. She has played a pivotal role in securing significant venture funding and positioning the company for clinical milestones, such as advancing the lead program MZE001 into Phase 1 trials, while fostering a robust financial framework to drive innovation in kidney disease therapies.